Rivaroxaban 2.5 mg

DRUG6 trials

Sponsors

The George Institute For Global Health, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen Scientific Affairs, LLC, Second Xiangya Hospital of Central South University, Imperial College London

Conditions

Acute Coronary SyndromeAtrial FibrillationCOVID-19Coronary SyndromeImprovement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood languageMyocardial InfarctionMyocardial IschemiaPercutaneous Coronary Intervention

Phase 3

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

CompletedNCT00809965

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia +1

Start: 2008-11-30End: 2011-09-30Updated: 2014-09-17

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

CompletedNCT01830543

Janssen Scientific Affairs, LLCAtrial Fibrillation, Percutaneous Coronary Intervention

Start: 2013-05-10End: 2016-07-28Updated: 2017-09-19

TRACK - Treatment of cardiovascular disease with low dose Rivaroxaban in Advanced CKD.

RecruitingCTIS2024-512483-59-00

The George Institute For Global HealthImprovement of cardiovascular outcomes in patients with advanced chronic kidney disease. In easily understood language, this is Heart and blood vessel disease and Kidney disease.

Start: 2023-06-09Target: 450Updated: 2025-01-07

Phase 4

Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome

CompletedNCT03363035

Second Xiangya Hospital of Central South UniversityAcute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia +1

Start: 2018-01-15End: 2021-11-30Updated: 2022-02-22

WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?

CompletedNCT04990791

Sheffield Teaching Hospitals NHS Foundation TrustCoronary Syndrome

Start: 2021-08-26End: 2023-12-01Updated: 2026-02-20

Unknown Phase

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.

TerminatedNCT04333407

Imperial College LondonCOVID-19

Start: 2020-04-03End: 2021-11-30Updated: 2023-01-18

Related Papers

U-shaped association between plasma cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) levels and myocardial infarction.

2025-02-19

Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial

Frontiers in Cardiovascular Medicine2024-01-0810 citations

Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome

JAMA Network Open2023-02-109 citations

COVID-19 and atherosclerosis: looking beyond the acute crisis

Emergency and Critical Care Medicine2022-01-2710 citations

Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial.

2021-12-2028 citations

Rationale and Design of the H-REPLACE Study: Safety and Efficacy of LMWH Versus Rivaroxaban in ChinEse Patients HospitaLized with Acute Coronary SyndromE.

2020-09-231 citations

Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis.

2020-01-0135 citations

Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation

Circulation Cardiovascular Interventions2019-11-013 citations

Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention

Circulation Cardiovascular Interventions2019-02-0111 citations

Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.

2018-10-0110 citations

Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome.

2018-07-019 citations

Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.

2018-03-1424 citations

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Circulation2016-11-1595 citations

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

New England Journal of Medicine2016-11-141525 citations

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).

2014-12-20102 citations

Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.

2013-04-1664 citations

Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).

2013-03-0758 citations

Rivaroxaban in patients with a recent acute coronary syndrome.

2011-11-131248 citations

Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.

2011-05-0159 citations